[go: up one dir, main page]

ATE262925T1 - Verbesserte arzneiverabreichung an schleimhautoberflächen - Google Patents

Verbesserte arzneiverabreichung an schleimhautoberflächen

Info

Publication number
ATE262925T1
ATE262925T1 AT98917414T AT98917414T ATE262925T1 AT E262925 T1 ATE262925 T1 AT E262925T1 AT 98917414 T AT98917414 T AT 98917414T AT 98917414 T AT98917414 T AT 98917414T AT E262925 T1 ATE262925 T1 AT E262925T1
Authority
AT
Austria
Prior art keywords
drug administration
improved drug
mucous surfaces
gel
administration
Prior art date
Application number
AT98917414T
Other languages
English (en)
Inventor
Peter James Watts
Lisbeth Illum
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10811025&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE262925(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Application granted granted Critical
Publication of ATE262925T1 publication Critical patent/ATE262925T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98917414T 1997-04-18 1998-04-20 Verbesserte arzneiverabreichung an schleimhautoberflächen ATE262925T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9707934.7A GB9707934D0 (en) 1997-04-18 1997-04-18 Improved delivery of drugs to mucosal surfaces
PCT/GB1998/001147 WO1998047535A1 (en) 1997-04-18 1998-04-20 Improved delivery of drugs to mucosal surfaces

Publications (1)

Publication Number Publication Date
ATE262925T1 true ATE262925T1 (de) 2004-04-15

Family

ID=10811025

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98917414T ATE262925T1 (de) 1997-04-18 1998-04-20 Verbesserte arzneiverabreichung an schleimhautoberflächen

Country Status (15)

Country Link
US (5) US6432440B1 (de)
EP (1) EP0975367B1 (de)
JP (3) JP2001524094A (de)
AT (1) ATE262925T1 (de)
CA (1) CA2282506C (de)
DE (2) DE122011000009I1 (de)
DK (1) DK0975367T3 (de)
ES (1) ES2221706T3 (de)
FR (1) FR11C0006I1 (de)
GB (2) GB9707934D0 (de)
NO (1) NO321729B1 (de)
NZ (1) NZ337289A (de)
PT (1) PT975367E (de)
WO (1) WO1998047535A1 (de)
ZA (1) ZA983262B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
ES2192781T3 (es) * 1997-08-26 2003-10-16 Aventis Pharma Inc Composicion farmaceutica para combinacion de piperidinoalcanol y un descongestivo.
US20040265377A1 (en) * 1997-10-27 2004-12-30 Harry Seager Solid dispersing vaccine composition for oral delivery
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
GB0000001D0 (en) * 2000-01-05 2000-02-23 Du Pont Uk Pharmaceutical compositions and their preparation
IL154041A0 (en) 2000-07-31 2003-07-31 Nycomed Danmark As Fentanyl composition for nasal administration
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2003213210A1 (en) 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic formulation with gum system
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
AU2003279750A1 (en) * 2002-06-28 2004-01-19 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
JP2006516262A (ja) * 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
SE0302947D0 (sv) * 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
KR101277367B1 (ko) * 2003-01-31 2013-06-20 디에스엠 아이피 어셋츠 비.브이. 카로티노이드를 포함하는 조성물
US20040248804A1 (en) * 2003-05-01 2004-12-09 Khurshid Iqbal Nasal administration of the LH-RH analog Leuprolide
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US20050113730A1 (en) * 2003-11-24 2005-05-26 Sca Hygiene Products Ab Absorbent Article Containing A Skin Care Product
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
EP1804824B1 (de) 2004-09-29 2017-01-04 Icahn School of Medicine at Mount Sinai Fsh- und fsh-rezeptor-modulatorverbindungen und verfahren zur verhinderung osteoklastischen knochenschwundes und knochenverlustes bei osteoporose
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US7786176B2 (en) 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
ES2378573T3 (es) 2006-03-16 2012-04-16 Tris Pharma, Inc. Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
DE602007012276D1 (de) 2006-10-04 2011-03-10 M & P Patent Ag Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern
JP5502494B2 (ja) 2007-01-22 2014-05-28 ターガセプト・インコーポレイテッド メタニコチンアナログの鼻腔内、バッカル、または舌下投与
JP2010520297A (ja) * 2007-03-02 2010-06-10 コーム インターナショナル リミテッド 麻酔薬スプレー組成物
EP2410985A2 (de) * 2009-03-26 2012-02-01 Pulmatrix, Inc. Verfahren zur behandlung und prophylaxe von pneumonie und tracheobronchitis im zusammenhang mit beatmungsgeräten
HUE040119T2 (hu) 2009-10-01 2019-02-28 Adare Pharmaceuticals Inc Orálisan alkalmazott kortikoszteroid készítmények
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
GB2482536B (en) 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
GB2482535A (en) * 2010-08-05 2012-02-08 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
JP5877201B2 (ja) 2010-08-30 2016-03-02 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
IL286573B (en) 2010-09-29 2022-08-01 Pulmatrix Operating Co Inc Monovalent metal cation dry powders for inhalation
US9433576B2 (en) 2010-09-29 2016-09-06 Pulmatrix, Inc. Cationic dry powders
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
EP2819672A1 (de) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalierbare trockenpulver
DK2884961T3 (en) 2012-08-15 2019-04-23 Tris Pharma Inc METHYLPHENIDATE TABLE WITH EXTENDED RELEASE
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US10130120B2 (en) 2013-03-15 2018-11-20 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP3166563B1 (de) * 2014-07-08 2020-12-16 Fertin Pharma A/S Orales abgabesystem mit zwei fächern
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
EP3355893A4 (de) 2015-09-29 2019-06-12 Kimberly-Clark Worldwide, Inc. Synergistische zusammensetzung zur erhaltung des gesunden gleichgewichts der mikroflora
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106511374A (zh) * 2016-10-20 2017-03-22 安徽宇宁果胶股份有限公司 一种果胶妇科抑菌凝胶及其制备方法
CN110234325A (zh) 2017-02-28 2019-09-13 金伯利-克拉克环球有限公司 用于维护微生物群落的健康平衡的协同组合物
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN112867815B (zh) * 2018-10-18 2024-11-29 奥野制药工业株式会社 铝合金的阳极氧化被膜用封孔处理液
CN112022880A (zh) * 2020-09-16 2020-12-04 杭州倍荣生物科技有限公司 一种直肠黏膜损伤及创面修复溶胶液及其制作方法
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US20210169783A1 (en) * 2019-12-09 2021-06-10 Nicoventures Trading Limited Oral products with controlled release
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
WO2022229833A1 (en) * 2021-04-26 2022-11-03 Politecnico Di Milano Gel for the regeneration of mucosae
EP4358748A1 (de) 2021-06-25 2024-05-01 Nicoventures Trading Limited Orale produkte und herstellungsverfahren

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125212A (en) * 1938-05-03 1938-07-26 Vick Chemical Company Therapeutic composition
US2730483A (en) * 1952-08-12 1956-01-10 Nepera Chemical Co Inc Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
NL284196A (de) * 1961-10-10
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
HU193780B (en) * 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja) * 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) * 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
US4826683A (en) * 1987-01-09 1989-05-02 Bates Harry L Decongestant
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) * 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE3827561C1 (de) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
JPH0597706A (ja) * 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9406171D0 (en) * 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
ATE180971T1 (de) * 1994-03-30 1999-06-15 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe
JP3911290B2 (ja) * 1994-05-13 2007-05-09 アラダイム コーポレーション エアゾールを含む麻酔用処方
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US6667279B1 (en) * 1996-11-13 2003-12-23 Wallace, Inc. Method and composition for forming water impermeable barrier
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
DE60044134D1 (de) * 1999-08-26 2010-05-20 Takeda Pharmaceutical Nasenschleimhaut haftende matrix
GB9924797D0 (en) * 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound

Also Published As

Publication number Publication date
US20070092535A1 (en) 2007-04-26
JP4880657B2 (ja) 2012-02-22
DE69822805D1 (de) 2004-05-06
EP0975367B1 (de) 2004-03-31
DE122011000009I1 (de) 2011-06-16
US20070110677A1 (en) 2007-05-17
DE69822805T2 (de) 2005-02-17
GB2340039B (en) 2002-02-06
NO995021D0 (no) 1999-10-15
DK0975367T3 (da) 2004-07-26
US20110182857A1 (en) 2011-07-28
CA2282506C (en) 2008-12-30
JP2009079052A (ja) 2009-04-16
GB9707934D0 (en) 1997-06-04
PT975367E (pt) 2004-08-31
AU741847B2 (en) 2001-12-13
WO1998047535A1 (en) 1998-10-29
US20020197324A1 (en) 2002-12-26
NZ337289A (en) 2001-06-29
ES2221706T3 (es) 2005-01-01
JP2001524094A (ja) 2001-11-27
GB9924123D0 (en) 1999-12-15
FR11C0006I1 (fr) 2011-04-08
JP2010280695A (ja) 2010-12-16
AU7064798A (en) 1998-11-13
NO995021L (no) 1999-10-15
NO321729B1 (no) 2006-06-26
ZA983262B (en) 1999-10-18
GB2340039A (en) 2000-02-16
CA2282506A1 (en) 1998-10-29
EP0975367A1 (de) 2000-02-02
US6432440B1 (en) 2002-08-13

Similar Documents

Publication Publication Date Title
ATE262925T1 (de) Verbesserte arzneiverabreichung an schleimhautoberflächen
IS4067A (is) PEG-Interferonafleiður, aðferð til framleiðslu þeirra, og notkunar sem lyfja
PT1410791E (pt) Forma galénica apta a ser administrada oralmente compreendendo metformina e um agente promotor da absorção
ATE286715T1 (de) Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
WO1998017315A3 (en) Permeation enhancers for transdermal drug delivery compositions, devices, and methods
EE9700192A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
ITRM910922A1 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
BR0013704A (pt) Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
BR0116972A (pt) Métodos e dispositivos para administração de substâncias na camada intradérmica da pele para absorção sistêmica
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
FR2753376B1 (fr) Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
MY127711A (en) Anti-vaginitis compositions for topical use
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
CO4960657A1 (es) Composicion farmaceutica
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
AU5587800A (en) S-(+)-desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
PT1276477E (pt) Medicamentos contendo acido pantotenico
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
GEP20032942B (en) Stabile Pharmaceutical Compositions Comprising Levosimendan and Alginic Acid
WO2001022917A8 (en) Effervescent compositions comprising nimesulide
IT1291895B1 (it) Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0975367

Country of ref document: EP

EEFA Change of the company name